Provided by Tiger Trade Technology Pte. Ltd.

Solid Biosciences

7.11
-0.6200-8.02%
Post-market: 7.110.00000.00%16:37 EDT
Volume:826.40K
Turnover:5.97M
Market Cap:699.56M
PE:-3.57
High:7.92
Open:7.73
Low:7.05
Close:7.73
52wk High:8.72
52wk Low:2.41
Shares:98.39M
Float Shares:58.54M
Volume Ratio:0.81
T/O Rate:1.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9922
EPS(LYR):-3.0550
ROE:-109.90%
ROA:-53.18%
PB:3.89
PE(LYR):-2.33

Loading ...

U.S. Earnings Preview: After Market Close March 18

Dow Jones
·
Mar 19

Solid Biosciences Is Maintained at Outperform by Wedbush

Dow Jones
·
Mar 12

Solid Biosciences price target raised to $17 from $14 at Wedbush

TIPRANKS
·
Mar 12

Solid Biosciences Publishes Updated Corporate Presentation Online

Reuters
·
Mar 12

Chardan Capital Issues a Buy Rating on Solid Biosciences (SLDB)

TIPRANKS
·
Mar 12

Solid Biosciences: Strengthened Dystrophin Data and Emerging Cardiac Benefits Support Buy Rating on SGT-003

TIPRANKS
·
Mar 12

Solid Biosciences Touts Encouraging Results For Duchenne Gene Therapy, FDA Talks Planned

Benzinga_recent_news
·
Mar 12

Solid Biosciences says interim results reinforce confidence in SGT-003 potential

TIPRANKS
·
Mar 12

Solid Biosciences reports 40 patients dosed in SGT-003 trial with 60% mean microdystrophin expression at day 90

Reuters
·
Mar 12

BRIEF-Solid Biosciences Provides Interim Positive Clinical Update On Phase 1/2 Inspire Duchenne Trial

Reuters
·
Mar 12

Solid Biosciences reports 60% microdystrophin expression in Phase 1/2 INSPIRE DUCHENNE trial of SGT-003

Reuters
·
Mar 12

Solid Biosciences Inc - Sgt-003 Generally Well Tolerated With Encouraging Safety Profile in 40 Participants

THOMSON REUTERS
·
Mar 12

Solid Biosciences Inc - Anticipates Dosing First Participant in Impact Duchenne Trial in Q1 2026

THOMSON REUTERS
·
Mar 12

Solid Biosciences Inc - Robust Microdystrophin Expression and Improved Muscle Integrity Observed After Sgt-003 Treatment

THOMSON REUTERS
·
Mar 12

Solid Biosciences: Plans for Additional Meetings With FDA in H1 2026 for Guidance on Potential Accelerated Approval Pathway for Sgt-003

THOMSON REUTERS
·
Mar 12

Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial

GlobeNewswire
·
Mar 12

Solid Biosciences trading halted, news pending

TIPRANKS
·
Mar 12

NASDAQ TRADE HALT HALT NEWS PENDING AT 12:55 PM

Reuters
·
Mar 12

Solid Biosciences Price Target Maintained With a $14.00/Share by Wedbush

Dow Jones
·
Mar 11

What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday?

Benzinga
·
Mar 10